Journal of Oncology / 2021 / Article / Tab 4

Research Article

Comparative Recurrence Analysis of Pancreatic Adenocarcinoma after Resection

Table 4

Independent prognostic factors for PFS.

CharacteristicsHeadBody/Tail
Univariate analysisMultivariate analysisUnivariate analysisMultivariate analysis
HR95% CIHR95% CIHR95% CIHR95% CI

Age≤60 yearsReference0.744ReferenceNIReference0.986ReferenceNI
>60 years1.0510.746–1.4811.0060.516–1.963
GenderFemaleReference0.525ReferenceNIReference0.537ReferenceNI
Male1.1200.790–1.5871.2320.636–2.387
WBC≤10Reference0.011Reference0.393Reference0.864ReferenceNI
>101.9651.165–3.3151.8550.450–7.6561.1910.161–8.825
NLR≤3.32Reference0.335ReferenceNIReference0.005Reference0.015
>3.321.1840.840–1.6683.3241.441–7.6693.3381.267–8.798
dNLR≤3.32Reference0.815ReferenceNIReference0.858ReferenceNI
>3.321.0450.723–1.5090.9420.492–1.804
PLR≤98.13Reference0.05Reference0.814Reference0.255ReferenceNI
>98.132.2721.001–5.1581.1120.460–2.6851.5010.746–3.018
PNI0Reference0.329ReferenceNIReference0.79ReferenceNI
11.2320.810–1.8721.1370.440–2.936
SII≤1000Reference0.837ReferenceNIReference0.106ReferenceNI
>10001.0370.732–1.4682.2290.843–5.898
mGPS0ReferenceReferenceNIReferenceReference
11.1220.895–1.4060.3190.6750.157–2.9110.5981.9600.212–18.1540.553
22.110.644–1.8890.2143.2510.592–17.8610.17513.6451.175–158.4590.037
PI0ReferenceReferenceReferenceReference
11.3461.038–1.7450.0250.9470.198–4.5310.9460.7080.094–5.3080.7370.2300.010–5.3820.361
21.2240.987–2.1140.0661.4960.327–6.8440.6042.4790.293–21.0060.4050.5460.117–3.5740.257
ALB (g/L)≤35Reference0.815ReferenceNIReference0.74ReferenceNI
>350.9490.614–1.4670.7830.184–3.329
CRP (ng/L)≤3Reference0.138ReferenceNIReference0.018Reference0.425
>31.2960.920–1.8252.8691.197–6.8771.5790.849–4.552
CA19-9 (U/ml)≤35Reference0.020Reference0.364Reference0.086ReferenceNI
>351.7621.094–2.8380.7740.445–1.3462.3470.885–6.225
CEA (ng/ml)≤5Reference0.010Reference0.007Reference0.320ReferenceNI
>51.5951.118–2.2741.7851.167–2.7301.3920.725–2.675
HBV infectionAbsenceReference0.997ReferenceNIReference0.331ReferenceNI
Presence0.9990.507–1.9662.7350.360–20.747
ChemotherapyNoReference0.054Reference0.001Reference0.690ReferenceNI
Yes1.3960.994–1.9610.4760.302–0.7491.1410.594–2.195
HemorrhageAbsenceReference0.990ReferenceNIReference0.585ReferenceNI
Presence1.0080.320–3.1700.5700.076–4.269
Pancreatic fistulaAbsenceReference0.407ReferenceNIReference0.237ReferenceNI
Presence1.1780.800–1.7330.5490.203–1.482
Biliary fistulaAbsenceReference0.971ReferenceNIReference0.873ReferenceNI
Presence0.9910.627–1.5681.0710.460–2.495
Abdominal infectionAbsenceReference0.313ReferenceNIReference0.348ReferenceNI
Presence1.3190.770–2.2572.6410.348–20.038
LN16AbsenceReferenceLAReference0.123ReferenceLAReferenceNI
Presence1.9390.835–4.503
Tumor differentiationWellReferenceLAReferenceNIReferenceLAReferenceNI
Moderate
Poor
Imaging tumor size (cm)≤2ReferenceLAReferenceReferenceLAReferenceNI
2–40.9740.425–2.2310.951
>41.7031.195–3.6480.029
Local progressionAbsenceReferenceLAReference<0.001ReferenceLAReferenceNI
Presence13.6437.279–25.569
Liver-only metastasisAbsenceReferenceLAReference<0.001ReferenceLAReferenceNI
Presence18.63210.506–33.043
Lung-only metastasisAbsenceReferenceLAReference<0.001ReferenceLAReferenceNI
Presence19.3137.054–52.877
Local + distant metastasisAbsenceReferenceLAReferenceReferenceLAReferenceNI
Presence13.5355.905–31.024<0.001
Multiple metastasesAbsenceReferenceLAReferenceNIReferenceLAReferenceNI
Presence33.9613.137–87.808
TNM stageIAReferenceLAReferenceReferenceLAReferenceNI
IB1.3820.476–4.0090.552
IIA1.2530.486–3.2320.64
IIB4.4011.537–12.6020.006
III1.7760.734–4.2990.203
Back membrane invasionAbsenceReferenceLAReference0.09ReferenceLAReferenceNI
Presence1.4600.943–2.262
LNR0ReferenceLAReferenceNIReferenceLAReferenceNI
0–0.160.4340.144–1.3060.137
>0.161.0430.576–1.8860.890
Positive LN number0ReferenceLAReferenceReferenceLAReferenceNI
1–30.4160.144–1.2030.106
>40.5870.274–1.5870.323
Pathological size (cm)≤2ReferenceLAReferenceNIReferenceLAReference
2–40.0990.016–0.6250.014
>40.5560.252–1.2270.146
Imaging LN size (cm)≤0.5ReferenceLAReferenceNIReferenceLAReference
0.5–1.50.2540.086–0.7510.013
>1.52.9990.813–11.0600.099
Imaging vascular invasionAbsenceReferenceLAReferenceNIReferenceLAReference0.239
Presence1.6700.712–3.919

NI, not included; LA, Included in LASSO analysis. Abbreviations as in Table 1.

Article of the Year Award: Outstanding research contributions of 2020, as selected by our Chief Editors. Read the winning articles.